What are the indications, dosing regimens, and contraindications for tenecteplase in adult patients with acute ST‑segment‑elevation myocardial infarction (STEMI) or acute ischemic stroke?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 3, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Tenecteplase: Indications, Dosing, and Contraindications

STEMI (ST-Elevation Myocardial Infarction)

Tenecteplase is FDA-approved to reduce mortality in acute STEMI, administered as a single weight-based IV bolus over 5 seconds 1.

Indications for STEMI

  • Acute STEMI when primary percutaneous coronary intervention (PPCI) cannot be achieved rapidly
  • Symptom onset within 12 hours (strongest benefit when given early, especially with large anterior infarctions and low bleeding risk) 2
  • May consider for symptomatic patients presenting 12-24 hours after onset with large myocardium at risk or hemodynamic instability if PCI unavailable 2

Dosing for STEMI

Weight-based single IV bolus over 5 seconds 2, 1:

  • <60 kg: 30 mg
  • 60-69 kg: 35 mg
  • 70-79 kg: 40 mg
  • 80-89 kg: 45 mg
  • ≥90 kg: 50 mg

Initiate as soon as possible after symptom onset. Tenecteplase is preferred over non-fibrin-specific agents due to superior patency rates and was equivalent to alteplase for 30-day mortality but with reduced non-cerebral bleeding in large trials 2.

Key Advantages in STEMI

The single bolus administration (versus alteplase's 90-minute infusion) makes tenecteplase particularly valuable for pre-hospital administration by paramedics and in rural/remote settings where rapid PCI access is impossible 3.

Acute Ischemic Stroke

For acute ischemic stroke within 4.5 hours, tenecteplase 0.25 mg/kg can be used as a safe and effective alternative to alteplase, with a strong recommendation for patients with large vessel occlusion 4.

Indications for Stroke

  • Acute ischemic stroke <4.5 hours from symptom onset 5, 4
  • Particularly favored for large vessel occlusion (LVO) stroke - tenecteplase 0.25 mg/kg is superior to alteplase in this population 4
  • May be considered for minor neurological impairment without major intracranial occlusion 5
  • Patients eligible for endovascular therapy should still receive IV thrombolysis first ("bridging therapy") 4

Dosing for Stroke

0.25 mg/kg as a single IV bolus 4, 6

This is half the dose used for STEMI - a critical distinction. The 0.40 mg/kg dose is specifically not recommended due to increased symptomatic intracranial hemorrhage without additional benefit 4, 6.

Current Evidence Status

While tenecteplase is not yet FDA-approved for stroke in the US, it has demonstrated:

  • Superior recanalization rates in LVO strokes 4, 7
  • Non-inferiority for 3-month disability-free outcomes 7
  • Similar safety profile to alteplase 4, 6
  • Meta-analyses show significant improvement in early neurological improvement (OR 1.52) and excellent functional outcomes (mRS 0-1: OR 1.19) with the 0.25 mg/kg dose 6

Important Limitations for Stroke

Do not use tenecteplase for wake-up stroke or unknown onset stroke selected only with non-contrast CT - this carries a strong recommendation against use 4. Advanced imaging (perfusion imaging) would be required in these scenarios.

Absolute Contraindications (Both Indications)

2, 1:

  • Any prior intracranial hemorrhage (ICH)
  • Active internal bleeding
  • Known structural cerebrovascular lesion (AVM, aneurysm)
  • Known malignant intracranial neoplasm
  • Ischemic stroke within 3 months (except acute ischemic stroke being treated)
  • Suspected aortic dissection
  • Significant closed-head or facial trauma within 3 months
  • Intracranial or intraspinal surgery within 2 months
  • Severe uncontrolled hypertension: SBP >180 mmHg or DBP >110 mmHg unresponsive to therapy
  • Known bleeding diathesis

Relative Contraindications

2:

  • Chronic severe poorly controlled hypertension
  • Significant hypertension on presentation (SBP >180 or DBP >110 mmHg)
  • Prior ischemic stroke >3 months ago
  • Dementia
  • Traumatic or prolonged CPR (>10 minutes)
  • Major surgery within 3 weeks
  • Recent internal bleeding (2-4 weeks)
  • Non-compressible vascular punctures
  • Pregnancy

Critical Safety Considerations

Bleeding Risk

Tenecteplase increases bleeding risk across all sites. Avoid intramuscular injections and non-compressible vascular punctures. Monitor closely for bleeding complications 1.

Administration Pitfalls

  • Dextrose incompatibility: Tenecteplase precipitates with dextrose-containing solutions. Flush all IV lines with 0.9% saline before and after administration 1
  • Reconstitute only with supplied Sterile Water for Injection
  • Use within 8 hours if refrigerated after reconstitution 1

Arrhythmias

Have anti-arrhythmic therapy available for bradycardia and ventricular irritability when administering tenecteplase 1.

Special Populations

For STEMI patients with large infarcts, physicians must choose either thrombolysis OR primary PCI as the primary strategy - combining planned PCI with thrombolysis increases heart failure and recurrent ischemia risk. However, rescue PCI or subsequent elective PCI after thrombolysis is appropriate 1.

Practical Algorithm

For STEMI:

  1. Symptom onset <12 hours + cannot achieve rapid PPCI → Give tenecteplase (weight-based STEMI dose)
  2. Transfer to PCI-capable center after administration
  3. Symptom onset 12-24 hours + large myocardium at risk or hemodynamic instability + no PCI available → Consider tenecteplase

For Acute Ischemic Stroke:

  1. Symptom onset <4.5 hours + no contraindications → Tenecteplase 0.25 mg/kg
  2. Large vessel occlusion present → Strongly favor tenecteplase 0.25 mg/kg over alteplase
  3. Endovascular therapy planned → Still give tenecteplase first (do not skip IV thrombolysis)
  4. Wake-up or unknown onset with only non-contrast CT → Do not give tenecteplase

References

Related Questions

What is tenecteplase and how is it administered for the treatment of an acute ischemic cerebrovascular accident (stroke)?
Is warfarin therapy a contraindication to tenecteplase (TNK)?
Can tenecteplase be given at the pulmonary embolism dose (0.5 mg/kg) for treatment of both pulmonary embolism and acute ischemic stroke?
What is the site of action of tenecteplase?
Is tenecteplase more effective for large‑vessel occlusion strokes than for small‑vessel (lacunar) strokes?
In a man with benign prostatic hyperplasia and chronic kidney disease, which alpha‑blocker is preferred and what is the appropriate dosing regimen?
In a patient with a fasting C‑peptide within the reference interval but inappropriately low relative to the fasting glucose, what does this indicate and what further evaluation and management steps are recommended?
What does a C‑peptide level of 2.3 ng/mL indicate about endogenous insulin production and the likely type of diabetes?
Can gluten intolerance cause post‑prandial dyspnea, and how should I differentiate an allergic reaction from gastrointestinal or cardiopulmonary causes?
What is the recommended treatment algorithm for managing ketosis‑prone diabetes, including initial insulin therapy, assessment of beta‑cell function, and transition to oral antidiabetic agents?
What is the pathogenesis of ketosis‑prone diabetes (KPD)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.